RxDoctor Payments Data

William Burden

Destin, FLNPI 1417038704

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,185 of the $40,189 with a category attached, or 72.6%. AbbVie accounts for 98.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $22,928 and has fallen 91.1% since, to $2,045 in 2025.

$40,189in general payments, 2019–2025

Across 357 payments — averaging $112.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • Galderma Laboratories, L.p.$251
  • Tepha Inc$159
  • Mentor Worldwide LLC$90
  • Revance Therapeutics, Inc.$66
  • Merz North America, Inc.$47
  • plus $94 from 4 others
$3,500in research payments, 2019–2025

Across 1 payment — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sientra, Inc.$4K

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$29,18573%
  • Travel & lodging$1,6434%
  • Food & beverage$9,06123%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$270
Scopolamine11$153
Promethazine Hcl19$95
Ondansetron Hcl17$37

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →